The latest price target for Inhibrx Biosciences (NASDAQ:INBX) was reported by JMP Securities on July 23, 2024. The analyst firm set a price target for $0.00 expecting INBX to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Inhibrx Biosciences (NASDAQ:INBX) was provided by JMP Securities, and Inhibrx Biosciences initiated their market perform rating.

There is no last upgrade for Inhibrx Biosciences

The last downgrade for Inhibrx Biosciences Inc happened on January 23, 2024 when JMP Securities changed their price target from N/A to N/A for Inhibrx Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inhibrx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inhibrx Biosciences was filed on July 23, 2024 so you should expect the next rating to be made available sometime around July 23, 2025.

While ratings are subjective and will change, the latest Inhibrx Biosciences (INBX) rating was a initiated with a price target of $0.00 to $0.00. The current price Inhibrx Biosciences (INBX) is trading at is $16.28, which is out of the analyst’s predicted range.